SF3B1 and myelodysplastic syndrome: As such, the most recent 2022 WHO Classification along with the 2022 International Consensus Classification (ICC) have moved away from relying on morphologic features and have defined a new genetic subtype: MDS with low blasts and SF3B1 mutations (MDS-SF3B1) [12,13].